Cancer Science and Targeted Therapy Conference

September 21-23, 2020

Venue
Mantra Bell City
215 Bell Street, Preston
VIC 3072, Australia
Conference Introduction

Session-1 Chemoresistance

To Trick a Transporter: Targeting Lysosomal P-glycoprotein with Innovative Multi-functional Anti-tumour Agents
Des R. Richardson, University of Sydney, New South Wales, Australia

Cancer Chemoresistance and ABC Drug Transporters
Suresh V. Ambudkar, NCI/NIH, MD, USA

Why do we need to know where drugs bind on P-gp?
Richard Callaghan, The Australian National University, Canberra, Australia

Keynote Talks

Targeting Stromal-Tumour Interactions in Pancreatic Cancer – An Effective Therapeutic Approach?
Minoti Apte, South Western Sydney Clinical School, Liverpool, Australia

Mechanism of Enhancing the Response to Checkpoint Inhibitors without Increasing Toxicity
Angus Dalgleish, St George’s, University of London, UK

Coffee Break

Session-2 Growth Factor Signalling

TGFBR2 Mediated Phosphorylation of BUB1 at Ser-318 is Required for Transforming Growth Factor-B Signaling
Shyam Nyati, University of Michigan, MI, USA

c-Met Activation Leads to the Establishment of a TGFβ-receptor Regulatory Network Required for Bladder Cancer Invasion
Pieter Eichhorn, Curtin University, Perth, Australia

Targeting Protein Synthesis and Growth Signalling in Prostate Cancer
Luc Furic, Monash University, Melbourne, Australia

The TWEAK/Fn14 Pathway as a Therapeutic Target in Hepatocellular Carcinoma and Cholangiocarcinoma
Nina Tirnitz-Parker, Curtin Health Innovation Research Institute, Perth, Australia

Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors
Kenny Chitcholtan, University of Otago, Christchurch, New Zealand

Lunch Break
Session-3  Lipid Signalling

Targeting Sphingolipid Metabolism in Acute Myeloid Leukemia
Stuart Pitson, University of South Australia and SA Pathology, Adelaide, Australia

Regulation of Phosphoinositide 3-kinase Signaling in Breast Cancer
Christina Mitchell, Monash University, Melbourne, Australia

Class II Phosphoinositide 3-kinase β and Cancer: A Novel Therapeutic Target?
Tania Maffucci, Queen Mary University of London, UK

Characterising Roles of the PTEN-PI3K Axis in Breast Tumorigenesis
Antonella Papa, Monash University, Melbourne, Australia

Identifying Optimal Strategies to Target S1P Signaling for the Attenuation of Cancer Progression and Chemotherapeutic Toxicity
Deron R. Herr, National University of Singapore, Singapore

Session-4  Extracellular Vesicles

Remote Control of Neuroblastoma Metabolism, Proliferation and Gene Expression through MYCN-Regulated Extracellular Vesicles
Arturo Sala, Brunel University London, UK

Pancreatic Cancer: Perspectives for a Brighter Prognosis
Marco Falasca, Curtin University, Perth, Australia

Exosomes Orchestrate Fibroblast-led Cancer Invasion – New Insights into Cancer Signalling
David Greening, Baker Heart and Diabetes Institute, Melbourne, Australia

Poster Presentations

P-01 Prognostic and Genetic Features of Multiple Primary Cancers of Esophageal Cancer
Pei-Wen Yang, National Taiwan University College of Medicine, Taiwan

P-02 UBXN2A Inhibits Tumor Invasion and Metastasis by Targeting the MTORC2/AKT Signaling Pathway
Sanam Sane, University of South Dakota, SD, USA

P-03 Metabolic Reprogramming as a Therapeutic Target of Pancreatic Cancer
Wen-Chun Hung, National Health Research Institutes, Taiwan

P-04 A Multicenter Study of the Impact of Body Mass Index on the incidence of Pathologic Complete Response Among Saudi Patients with locally advanced Breast cancer post Neoadjuvant Chemotherapy
Arwa Abdelmogod, Prince of Wales Hospital, Australia

P-05 Association of Age with Clinical Subtypes of Depression Symptoms in Breast Cancer Patients: A Latent Class Analysis
Yanyan Li, Shandong University, China

P-06 Early Detection of Intrahepatic Cholangiocarcinoma
Magdalena Sejka, The Royal Melbourne Hospital, Melbourne, Australia

P-07 Longitudinal Association of Subjective Prospective and Retrospective Memory and Depression among Patients with Glioma
Xuan Zhang, Shandong University, China
Session-5  Novel Therapeutics Target in Cancer

**Restoration of Tumour Suppression to Treat wt and Mutant p53 Hormone Related Cancers**
Ygal Haupt, Peter MacCallum Cancer Centre, Melbourne, Australia

**Functional Genomic Approaches to Identify new Wnt/b-catenin Regulators in Colorectal Cancer**
Ron Firestein, Director, Cancer Centre at Hudson Institute, Monash University, Melbourne, Australia

**Ophiobolin A: A Promising Antiglioblastoma Agent**
Alexander Kornienko, Texas State University, TX, USA

**Targeting the MTORC2 Pathway in Obesity-Associated Colorectal Cancer**
Khosrow Rezvani, University of South Dakota, SD, USA

**Investigation of miRNA and mRNA Co-expression Network in Ependymoma**
Tao Huang, Chinese Academy of Sciences, China

Coffee Break

Session-6  Cancer Immunotherapy

**Immune Landscape Sculptured by the Peritoneal Microenvironment that supports Metastases arising from Colorectal Primary Tumours**
Robert G. Ramsay, Peter MacCallum Cancer Centre, Melbourne, Australia

**Immunotherapy of Solid Tumor with the Third Generation TCR-T**
Yi Li, Guangzhou Institutes of Biomedicine and Health, China

**Deciphering the Role of CD70/CD27 in Oncology**
Julie Jacobs, Scientist, Argenx Inc., Belgium

**Cancer Immunotherapy by Targeting TGF-B/Smad3**
Guangyu Lian, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong

**Distribution and Functions of CD39+f5 Tregs Infiltrated in the Microenvironment of Left/Right-Sided Colorectal Cancer**
Zhan Yang, Tianjin Medical University Cancer Institute and Hospital, China

Lunch Break
Session-7  Tumor Microenvironment and Cancer Stem Cells

Novel Nanomedicine Shuts Down Metabolic Cellular Cross-talk Which Reduces Fibrosis and Pancreatic Tumour Progression  
Phoebe Phillips, Prince of Wales Clinical School, UNSW Medicine NSW, Australia

Targeting Cell-Cell Communication in Tumours and the Tumour Microenvironment  
Peter Janes, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia

Proteomic Profiling of the Prostate Tumour Microenvironment Reveals LOXL2 as a Therapeutic Target  
Natalie Lister, Monash University, Melbourne, Australia

The Prognostic Value of S100A10 in Cancer  
Normastuti Adhini Tantyo, Indonesia International Institute for Life Sciences, Indonesia

Coffee Break

Session-8  Cancer Targeted Therapy

Regulation of the Hypoxia Transcription Factors by Ascorbate and Potential Implications for Cancer Patients  
Gabi Dachs, University of Otago, Christchurch, New Zealand

Repurposing Flubendazole as a Small Molecule Inhibitor of Programmed Cell Death Protein-1  
Levon M. Khachigian, University of New South Wales, Sydney, Australia

Discovery of Novel Targetable Pathways and Drug Molecules for Infant Acute Lymphoblastic Leukaemia  
Klaartje Somers, Children’s Cancer Institute, Sydney, Australia

EDNRB Isoform 3 Confers Temozolomide Resistance in Human Melanoma Cells by Modulating Membrane Potential, Reactive Oxygen Species and Mitochondrial Ca2+  
Long Cui, Guangzhou Women and Children’s Medical and The Chinese University of Hong Kong, Hong Kong

Longitudinal Association of Subjective Prospective and Retrospective Memory and Depression among Patients with Glioma  
Xuan Zhang, Shandong University, China

Poster Presentations
SMAD Proteins Directly Suppress PAX2 Transcription Downstream of Transforming Growth Factor Beta 1 Signalling in Renal Cell Carcinoma
Michael Eccles, University of Otago, Christchurch, New Zealand

Pharmacologically Targetable Vulnerability in Prostate Cancer Carrying RB1-SUCLA2 Deletion
Chiaki Takahashi, Cancer Research Institute, Kanazawa University, Japan

High Methylation of ZNF582/PAX1 in Cervical Cancer Affected Radio-chemo and Neoadjuvant Chemotherapy Sensitivity and Prognosis
Yuligh Liou, Xiangya Medical Laboratory, Central South University, China

Clinical Application of Tube-chip Digital PCR for Accurate Detection of Gene Mutation in Cancer Patients
Xiwen Jiang, DAAN Gene Co., Ltd. of Sun Yat-sen University, China